Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling
Gerardo García‐Rivas, Omar Lozano, Judith Bernal‐Ramírez, Christian Silva‐Platas, Felipe Salazar‐Ramírez, Abraham Méndez‐Fernández, Carolina A. Morales‐Ochoa, Hugo Alves‐Figueiredo, Martin Ramos-González, Néstor Rubio‐Infante, Eduardo Vázquez‐Garza, Luis Alberto Luévano‐Martínez, Silvia López‐Morán, Héctor Chapoy‐Villanueva, James Bolton, José-Luis Velasco-Bolom, Paola Mendoza-Espinosa, Flavio F. Contreras‐Torres, Carlos Jerjes-Sánchez, Guillermo Torre‐Amione
Abstract
Heart failure (HF) is characterized by energy deprivation, calcium (Ca2+) handling alterations, and inflammation: effects associated with mitochondrial dysfunction. Cannabidiol previously prevented mitochondrial dysfunction. Thus, it may prevent HF progression. In mice with HF, subcutaneous cannabidiol attenuated cardiac fibrosis, hypertrophy, loss of ejection fraction, and inflammation; isolated cardiomyocytes preserved cell shortening, Ca2+ handling, mitochondrial function and redox balance. Hypertrophied ventricular cardiomyoblasts suggested cannabidiol-mediated effects through peroxisome proliferator-activated gamma receptors. Therefore, cannabidiol in HF limited cardiac hypertrophy and preserved contractile function by sustaining cardiomyocyte and mitochondrial function through redox balance maintenance, supporting cannabidiol role as a cardioprotective therapy in HF.